Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 16/20 | 1.00 |
| ▸ | DRD3 | P35462 | 15/20 | 1.00 |
| ▸ | DRD4 | P21917 | 5/20 | 0.65 |
| ▸ | HTR1A | P08908 | 1/20 | 0.65 |
| ▸ | HTR2A | P28223 | 1/20 | 0.65 |
| ▸ | HTR2C | P28335 | 1/20 | 0.65 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.62 |
| ▸ | BCL2A1 | Q16548 | 1/20 | 0.61 |
| ▸ | DRD5 | P21918 | 1/20 | 0.55 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | RAD52 | P43351 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3399574 | 0.93 | DRD2 (0.87) | DRD2DRD3DRD4HTR1AHTR2A | |
| SCHEMBL424507 | 0.86 | DRD2 (0.75) | DRD2DRD3DRD4HTR1AHTR2A | |
| SCHEMBL12359055 | 0.83 | DRD2 (0.71) | DRD2DRD3DRD4HTR1AHTR2A | |
| SCHEMBL3398184 | 0.82 | DRD2 (0.70) | DRD2DRD3DRD4ADRB1DRD5 | |
| SCHEMBL8452211 | 0.82 | DRD2 (0.69) | DRD2DRD3DRD4ADRB1DRD5 | |
| SCHEMBL24309229 | 0.81 | DRD2 (0.69) | DRD2DRD3DRD4HTR1AHTR2A | |
| SCHEMBL6002186 | 0.81 | DRD2 (0.69) | DRD2DRD3DRD4HTR1AHTR2A | |
| SCHEMBL3597338 | 0.81 | DRD2 (0.69) | DRD2DRD3DRD4HTR1AHTR2A | |
| SCHEMBL2782258 | 0.81 | DRD2 (1.00) | DRD2DRD3DRD4HTR1AHTR2A | |
| SCHEMBL8318459 | 0.81 | DRD2 (0.68) | DRD2DRD3DRD4HTR2AADRB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3250209-B1 | COMT INHIBITING METHODS AND COMPOSITIONS | LIEBER INST FOR BRAIN DEVELOPMENT (US) | 2023-09-13 | — | — | EP | disclosed |
| US-20230076435-A1 | MODIFIER OF FOUR-MEMBERED RING DERIVATIVE, PREPARATION METHOD AND APPLICATION THEREOF | SHANGHAI HANSOH BIOMEDICAL CO., LTD. (CN) | 2023-03-09 | — | — | US | disclosed |
| WO-2022187206-A1 | DUAL-TARGET MU OPIOID AND DOPAMINE D3 RECEPTORS LIGANDS; PREPARATION AND USE THEREOF | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2022-09-09 | — | — | WO | disclosed |
| EP-4053110-A1 | MODIFIER OF FOUR-MEMBERED RING DERIVATIVE, PREPARATION METHOD AND APPLICATION THEREOF | Shanghai Hansoh Biomedical Co., Ltd. (CN) | 2022-09-07 | — | — | EP | disclosed |
| WO-2021083246-A1 | MODIFIER OF FOUR-MEMBERED RING DERIVATIVE, PREPARATION METHOD AND APPLICATION THEREOF | 上海翰森生物医药科技有限公司 | 2021-05-06 | — | — | WO | disclosed |
| WO-2020156312-A1 | POLYCYCLIC DERIVATIVE MODULATOR, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | 江苏豪森药业集团有限公司 | 2020-08-06 | — | — | WO | disclosed |
| US-10479790-B2 | COMT inhibiting methods and compositions | LIEBER INSTITUTE FOR BRAIN DEVELOPMENT (US) | 2019-11-19 | — | — | US | disclosed |
| US-20160222011-A1 | COMT Inhibiting Methods and Compositions | LIEBER INSTITUTE, INC. | 2016-08-04 | — | — | US | disclosed |
| US-8580786-B2 | Triazine derivatives and their therapeutical applications | NANT HOLDINGS IP, LLC (US) | 2013-11-12 | — | — | US | disclosed |
| WO-2012003418-A2 | FUNCTIONALLY SELECTIVE LIGANDS OF DOPAMINE D2 RECEPTORS | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2012-01-05 | — | — | WO | disclosed |
| US-20090238761-A1 | Novel Aryl Piperazine Derivatives With Medical Utility | UNIVERSITA DEGLI STUDI DI SIENA (IT) | 2009-09-24 | — | — | US | disclosed |
| US-20090238761-A1 | Novel Aryl Piperazine Derivatives With Medical Utility | UNIVERSITA DEGLI STUDI DI SIENA (IT) | 2009-09-24 | — | — | US | disclosed |
| US-20070259881-A1 | Substituted Imidazo Ring Systems and Methods | COLEY PHARMACEUTICAL GROUP, INC. | 2007-11-08 | — | — | US | disclosed |
| US-20070259881-A1 | Substituted Imidazo Ring Systems and Methods | COLEY PHARMACEUTICAL GROUP, INC. | 2007-11-08 | — | — | US | disclosed |
| EP-1625116-B1 | PROCESS FOR THE PREPARATION OF CARBOSTYRIL DERIVATIVES,SUCH AS ARIPIPRAZOLE AND ITS INTERMEDIATES | DELMAR CHEMICALS INC (CA) | 2007-08-08 | — | — | EP | disclosed |
| US-20070142399-A1 | Dual function drugs and uses thereof | PSYCHIATRIC GENOMICS, INC. (US) | 2007-06-21 | — | — | US | disclosed |
| US-5945421-A | TREATING PSYCHOSIS AND SCHIZOPHRENIA | WARNER-LAMBERT COMPANY (US) | 1999-08-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230076435-A1 | MODIFIER OF FOUR-MEMBERED RING DERIVATIVE, PREPARATION METHOD AND APPLICATION THEREOF | GRM4, GRM5, GRIA4 | DRD2 343/4885DRD3 367/4885DRD4 387/4885 |
| US-20070259881-A1 | Substituted Imidazo Ring Systems and Methods | IL2, IL4, IRF3 | DRD2 2894/4885DRD3 2290/4885DRD4 2223/4885 |
| US-20160222011-A1 | COMT Inhibiting Methods and Compositions | COMT, SLC6A3, MAOA | DRD2 313/4885DRD3 477/4885DRD4 263/4885 |
| US-10479790-B2 | COMT inhibiting methods and compositions | COMT, SLC6A3, MAOA | DRD2 313/4885DRD3 477/4885DRD4 263/4885 |
| US-20090238761-A1 | Novel Aryl Piperazine Derivatives With Medical Utility | HTR2C, HTR2A, DRD2 | DRD2 3/4885DRD3 10/4885DRD4 19/4885 |
| US-20070142399-A1 | Dual function drugs and uses thereof | COMT, DRD2, SLC6A3 | DRD2 2/4885DRD3 7/4885DRD4 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.